Brief: Spyre Therapeutics Spy003 First-In-Human Dosing Now Expected Q1 2025
14/10/2024 13:09
Oct 14 (Reuters) - Spyre Therapeutics Inc SYRE.O :
* SPYRE THERAPEUTICS INC: SPY003 FIRST-IN-HUMAN DOSING NOW
EXPECTED Q1 2025
* SPYRE THERAPEUTICS: EXPECTS TO SHARE INTERIM DATA FROM
ACCELERATED FIRST-IN-HUMAN SPY003 TRIAL IN H2 2025
Source text for Eikon: ID:nPn4md1jLa
Further company coverage: SYRE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spyre Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
U.S. STOCKS ON THE MOVE-MYR Group, Spyre Therapeutics, AMD
Spyre Therapeutics slips on $350 mln share sale
Brief: Spyre Therapeutics Announces Pricing Of $350.0 Million Public Offering Of Common Stock